Search

Your search keyword '"Drayson M"' showing total 62 results

Search Constraints

Start Over You searched for: Author "Drayson M" Remove constraint Author: "Drayson M" Database Unpaywall Remove constraint Database: Unpaywall
62 results on '"Drayson M"'

Search Results

1. Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry

3. Establishing the prevalence of common, clinically relevant tissue-specific autoantibodies following SARS CoV-2 infection

4. Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients

6. S873 EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK

9. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

10. High versus attenuated dose dexamethasone has little effect on the speed or depth of response to induction therapy for myeloma

12. Presentation free light chain levels and age are the strongest predictors of renal function in newly diagnosed multiple myeloma patients

14. The quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) is safe and well tolerated as induction therapy for newly diagnosed, transplant eligible, myeloma patients

17. Guidelines for the correct determination of second primary malignancies in myeloma trials

21. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate

24. Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results.

25. Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial.

26. Defining the biological subgroup of multiple myeloma patients which benefits maximally from the overall survival (OS) benefit associated with treatment with zoledronic acid (ZOL).

Catalog

Books, media, physical & digital resources